Cell Expansion Market is predicted to reach USD 39.3 billion at a CAGR of 13.00% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cell Expansion Market”.

The Cell Expansion Market is estimated to register a CAGR of 13.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Cell Expansion Market— Thermo Fisher Scientific, Inc., GE Healthcare, Corning, Inc., STEMCELL Technologies, Inc., Merck KGaA, Miltenyi Biotec, Becton, Dickinson and Company, Terumo Bct, Inc., Sartorius AG, Takara Bio, Inc.

Cell Expansion Market Highlights

The global Cell Expansion Market is accounted to register a CAGR of 13.00% during the forecast period and is estimated to reach USD 39.3 billion by 2032.

Some factors contributing to the global Cell Expansion market's growth include increased R&D spending in cell-based research, a growing emphasis on personalized medicine, and an increase in the number of strategic alliances for the discovery of innovative therapies. However, ethical concerns about cell biology and the high expense of cell-based therapies are projected to limit market expansion.

Segmental Analysis

The global Cell Expansion Market has been segmented based on Product, Cell Type, Application and End-use.

The market is segmented by product into Consumables [Reagents, Media, & Serum, Other Consumables], Culture Flasks and Accessories [Tissue Culture Flasks, Other Culture Flasks and Accessories], Instruments [Automated Cell Expansion Systems, Bioreactors, and Other Instruments. The consumables category led the market in 2023 due to the availability of a diverse range of commercial media and reagents customized to certain types of cells. These products are also widely available and ready to use and come in serum-free compositions.

The market is segmented by Cell Type into Mammalian [Human], Animal, and Others. The mammalian segment had the maximum revenue share in 2023 and is predicted to maintain its dominance during the forecast period, as these culture systems are highly chosen for the creation of complex protein therapies. This is because these systems have pharmacokinetic and physiological relevance to post-translational changes in humans.

Application has divided the worldwide Cell Expansion Market into biopharmaceuticals, tissue culture & engineering, vaccine production, drug development, gene therapy, cancer research, stem cell research and others. The biopharmaceuticals segment is expected to experience the fastest growth rate during the forecast period. The increased need for biopharmaceuticals such as vaccines, monoclonal antibodies, and therapeutic proteins due to the increasing prevalence of chronic diseases is expected to drive the expansion of the biopharmaceutical production segment in the approaching years.

The global Cell Expansion Market is divided into three segments based on End-use: biopharmaceutical & biotechnology companies, research institutes, cell banks, and others. The biopharmaceutical & biotechnology companies section had the greatest share in 2023 and is expected to increase rapidly in the next years. The expanding horizon of cell-based treatments in the healthcare business is one of the primary reasons for biopharmaceutical & biotechnology’s huge market share.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cell Expansion Market Research Report

Regional Analysis

The global Cell Expansion Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Cell Expansion Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Cell Expansion Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Cell Expansion Market comprises the Middle East, Africa, and Latin America.

North America had the greatest revenue share in 2023. The region is expected to maintain its leadership position in the next years as a result of increased government funding programs that have advanced stem cell production as well as the development of regenerative medicines and cellular therapies. This, in turn, increases demand for cell expansion platforms in the region.

Moreover, Europe's cell expansion industry is predicted to increase significantly as market participants expand their facilities and engage in cell and gene therapy production. For instance, in March 2021, GSK, a science-led global healthcare company, announced an agreement with Cell and Gene Therapy Catapult, a non-profit organization dedicated to the advancement of cell and gene therapies through creativity and technology, to expand its clinical trial manufacturing capacity for cell and gene therapy at the Cell and Gene Therapy Catapult facility in Stevenage, United Kingdom.

Additionally, Asia Pacific is predicted to have the quickest CAGR throughout the projection period, owing to increased efforts by various local pharmaceutical and biotechnology businesses to develop and commercialize cellular treatments. In September 2022, Alkem Laboratories and Stempeutics announced the first off-the-shelf cell therapy product, "StemOne," for treating knee osteoarthritis in India. The medication has obtained regulatory approval from India's Drugs Controller General, making it the country's first allogeneic cell therapy product approved for commercial usage.

The remaining Cell Expansion Market is segmented into three regions: the Middle East, Africa, and Latin America. These regions will maintain their leadership position in the next years due to increasing government funding initiatives that have accelerated the development of regenerative medicine, cellular therapy products, and stem cell manufacturing.

Key Findings of the Study

• The global Cell Expansion Market is expected to reach USD 39.3 billion by 2032, at a CAGR of 13.00% during the forecast period.


• Asia Pacific is predicted to have the quickest CAGR throughout the projection period, owing to increased efforts by various local pharmaceutical and biotechnology businesses to develop and commercialize cellular treatments.


• Based on end-use, the biopharmaceutical and biotechnology companies section had the greatest share in 2023.


• Thermo Fisher Scientific, Inc., GE Healthcare, Corning, Inc., STEMCELL Technologies, Inc., Merck KGaA, Miltenyi Biotec, Becton, Dickinson and Company, Terumo Bct, Inc., Sartorius AG, and Takara Bio, Inc. are the key market players.